4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-17-049451
EVP & Chief Strategy Officer sold 9,464 shares at an average $14.88 ($140,802)
- EVP & Chief Strategy Officer acquired 4,145 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Soffer Gad EVP & Chief Strategy Officer | 2017-08-15 | Sale | −7,000 | $15.00 | $105,000 | 257,409 | D |
| Soffer Gad EVP & Chief Strategy Officer | 2017-08-15 | Option exercise | +4,145 | 261,554 | D | ||
| Soffer Gad EVP & Chief Strategy Officer | 2017-08-16 | Sale | −2,464 | $14.53 | $35,802 | 259,090 | D |
| Derivatives | |||||||
| Soffer Gad EVP & Chief Strategy Officer | 2017-08-15 | Option exercise · Restricted Stock Units | −4,145 | 6,910 | D | ||
| Open-market sales · 9,464 sh · avg $14.88 · $140,802 | |||||||
Loading xslF345X03/doc4.xml…